{"disease":{"id":"plexiform-neurofibromas-pn","name":"plexiform neurofibromas pn"},"drugs":{"marketed":[{"drug_id":"selumetinib","indication_name":"Treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Koselugo","generic_name":"selumetinib","company_name":"ASTRAZENECA LP","drug_phase":"marketed","molecular_target":"AP2-associated protein kinase 1","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2)."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06763315","title":"Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT02407405","title":"MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03649165","title":"A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}